tetano
Editor, Senior Moderator
ACS Appl Mater Interfaces
. 2022 Jan 27.
doi: 10.1021/acsami.1c19192. Online ahead of print.
Polycationic HA/CpG Nanoparticles Induce Cross-Protective Influenza Immunity in Mice
Chunhong Dong[SUP] 1 [/SUP], Ye Wang[SUP] 1 [/SUP], Wandi Zhu[SUP] 1 [/SUP], Yao Ma[SUP] 1 [/SUP], Joo Kim[SUP] 1 [/SUP], Lai Wei[SUP] 1 [/SUP], Gilbert X Gonzalez[SUP] 1 [/SUP], Bao-Zhong Wang[SUP] 1 [/SUP]
Affiliations
Abstract
The intranasal (i.n.) route is an ideal vaccination approach for infectious respiratory diseases like influenza. Polycationic polyethylenimine (PEI) could form nanoscale complexes with negatively charged viral glycoproteins. Here we fabricated PEI-hemagglutinin (HA) and PEI-HA/CpG nanoparticles and investigated their immune responses and protective efficacies with an i.n. vaccination regimen in mice. Our results revealed that the nanoparticles significantly enhanced HA immunogenicity, providing heterologous cross-protection. The conserved HA stalk region induced substantial antibodies in the nanoparticle immunization groups. In contrast to the Th2-biased, IgG1-dominant antibody response generated by PEI-HA nanoparticles, PEI-HA/CpG nanoparticles generated more robust and balanced IgG1/IgG2a antibody responses with augmented neutralization activity and Fc-mediated antibody-dependent cellular cytotoxicity (ADCC). PEI-HA/CpG nanoparticles also induced enhanced local and systemic cellular immune responses. These immune responses did not decay over six months of observation postimmunization. PEI and CpG synergized these comprehensive immune responses. Thus, the PEI-HA/CpG nanoparticle is a potential cross-protective influenza vaccine candidate. Polycationic PEI nanoplatforms merit future development into mucosal vaccine systems.
Keywords: cross-protection; influenza vaccine; intranasal vaccination; polyethylenimine; recombinant protein vaccine.
. 2022 Jan 27.
doi: 10.1021/acsami.1c19192. Online ahead of print.
Polycationic HA/CpG Nanoparticles Induce Cross-Protective Influenza Immunity in Mice
Chunhong Dong[SUP] 1 [/SUP], Ye Wang[SUP] 1 [/SUP], Wandi Zhu[SUP] 1 [/SUP], Yao Ma[SUP] 1 [/SUP], Joo Kim[SUP] 1 [/SUP], Lai Wei[SUP] 1 [/SUP], Gilbert X Gonzalez[SUP] 1 [/SUP], Bao-Zhong Wang[SUP] 1 [/SUP]
Affiliations
- PMID: 35084819
- DOI: 10.1021/acsami.1c19192
Abstract
The intranasal (i.n.) route is an ideal vaccination approach for infectious respiratory diseases like influenza. Polycationic polyethylenimine (PEI) could form nanoscale complexes with negatively charged viral glycoproteins. Here we fabricated PEI-hemagglutinin (HA) and PEI-HA/CpG nanoparticles and investigated their immune responses and protective efficacies with an i.n. vaccination regimen in mice. Our results revealed that the nanoparticles significantly enhanced HA immunogenicity, providing heterologous cross-protection. The conserved HA stalk region induced substantial antibodies in the nanoparticle immunization groups. In contrast to the Th2-biased, IgG1-dominant antibody response generated by PEI-HA nanoparticles, PEI-HA/CpG nanoparticles generated more robust and balanced IgG1/IgG2a antibody responses with augmented neutralization activity and Fc-mediated antibody-dependent cellular cytotoxicity (ADCC). PEI-HA/CpG nanoparticles also induced enhanced local and systemic cellular immune responses. These immune responses did not decay over six months of observation postimmunization. PEI and CpG synergized these comprehensive immune responses. Thus, the PEI-HA/CpG nanoparticle is a potential cross-protective influenza vaccine candidate. Polycationic PEI nanoplatforms merit future development into mucosal vaccine systems.
Keywords: cross-protection; influenza vaccine; intranasal vaccination; polyethylenimine; recombinant protein vaccine.